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emergency depatiments. An ability to use a personal computer (PC) and
nonproprietary software/hardware would be convenient and cost-effective.
To determine interpretive concordance from a remote-site PC, 2 blinded ob-
servers re-scored 26 consecutive TI-201 studies that had been previously
interpreted in our lab. SPECT and planar (anterior and LAO-459 views)
images were modem transferred to an Internet Web page. Images were
displayed in standard format using an 8 bit grey scale, 1 mb video card, 800
x 600 resolution, 17” monitor, and a Pentium 100 mHz computer. Quality
was judged adequate-high for all studies. Descriptive data: 68% male, 76%
known CAD, 52% prior Ml, 32% prior CABG, 68% prior PTCA, 52% exercise
stress. Results (all p = ns) (MVD = multivessel CAD).
Normal Ischemia
Any MVD LAD RCA LCX
NuclLab 7 18 11 11 13 10
RemotePC 8 17 10 12 12 10
Byindividual pt, concordances foranyabnormality, for MVD, and vascular
territory of abnormality were 83Y0,61%, and 85% respectively. Conclusion:
This study of relatively complex scans establishes the clinical feasibility of
interpretation using the Internet and a generic display configuration. Fur-
ther studies are indicated to determine whether additional data or different
hardware may improve results.
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m The(R)-and(s)-~nan~iom~r~ofBeti-B1ockersAreDifferentDrugs
K.Stoschitzky,W. Lindner 1, W. Klein. Department of Medicine/Division of
Cardiology, Graz, Austria, 1 Institute of Pharmaceutical C/rernist~, Karl
Franzens University Graz, Austria
In order to investigate the clinical impact of chirality in beta-blocking drugs,
we performed two randomized, double-blind, cross-over studies with two
groups of 12 healthy volunteers who received single oral doses of 40 mg
(R)- and 40 mg (S)-propranoiol, or 50 mg (R)- and 50 mg (S)-atenolol,
respectively, at intervals of 1 week. Exercise was performed prior to and
4 hours after drug intake, blood samples were taken immediately before
and after exercise. Compared with baseline, heart rate during exercise was
reduced by (S)-propranoiol (-22%, p < 0.001) and (S)-atenolol (–25%, p c
0.001) whereas the (R)-enantiomers had no effect. At rest, the mean plasma
concentration of (S)-propranolol was higher (+26%, p < 0.001) than that of
(R)-propranolol, whereas that of (S)-atenolol was lower (–3%, p < 0.01) than
that of (R)-atenolol. Exercise caused an increase of plasma concentrations
of (S)-propranolol (+25%, p < 0.001) and (S)-atenolol (+44%, p < 0.001)
whereas those of the (R)-enantiomers remained unaffected.
These date demonstrate profound and clinically significant, pharma-
codynamic and pharmaookinetic differences between the (R)- and (S)-
enantiomers of propranolol as well aa those of atenolol. Therefore, we
suggest that the (R)- and (S)-enantiomerS of beta-blocking drugs should
be recognized and used as individual drugs by themselves rather than just
as “the enantiomem” of racemic drugs. According to the present state of
the art, the currently used racemic mixtures should no longer be regarded
as the best possible remedies in beta-blocker therapy, they rather,should
be replaced by the optically pure (S)-enantiomers which can nowadays be
provided easily and at low costs.
m1027174 DecreasedCholeeterylEaterificationby@-blockerAgentsinHumanOxidizedLow
DensityLipoprotein
C. Napoli 12, F.P.D’Armiento3, S. Lepore’, A. Scognamiglio 1,G. Corso4,
M. Condorelli 1, M. Chiariello’, G. Ambrosio ”5. 1Division of Cardiology
Institute of Internal Medicina, Cardiology and Cardiosur9a042Department
of Clinical and Experimental Medicine, 3 Institute of Human Pathology
4Depatiment of Biochemistry and Medical Technology School of Medicine,
Fedarico // University of fVaplas, Italx 5Division of Cardiology University of
Perugia, Italy
Oxidized low density lipoprotein (LDL) taken up by macrophages via the
scavenger receptor may contribute to formation of intimal foam ceils. We
have previously reporb?dthat several fl-blockeragents have variable degrees
of antioxidant potency on LDL. Moreover, previous studies have shown that
p-blocker agents reduce experimental atherosclerosis in primates. Thus,
in this study we investigated whether fl-blceker agents may prevent LDL
cholesteyl esterification induced by oxygen radicals, a key event in foam cell
formation. Purified human LDL were exposed to oxygen radicals generatad
by CUS04 (15 MMfor 20 hours at 37~C)under control conditions, or after a
30 minute pre-incubation with the p-blocker agent propranolol, metoprolol,
and acebutolol (1 and 3 KM of concentration).
p-Blocker Propranolol Metoprolol Acebutolol
Dose (uM) 1 3 1 3 1 3
MDA (4Areduction) –35* -57” –22 –42* –20 –43”
CE (ControlOXLDL54 + 3) 28+ 2“ 14 +2* 34 + 2 19 + 2* 38 + 2 22 +2*
Legend.MDA: malondialdehyde;CE: cholesterolesters (nmolfmgcell proteirV12hs). * p
<0,05 w relativecontrols.
Ourdatademonstrate that j?-blockeragents exert a decrease on choleateryl
esterification formation. These results were achieved with concentrations of
potentially clinically use. Although these drugs are known to adversely af-
fect lipid metabolism, inhibition of both oxidative compounds and cholesterol
esterification may reduce uptake of oxidized LDL and hence foam cell for-
mation.
I 1027-I75I Nipracfilol,aNitricOxidaReleasing
Beta-BlockingAgent,Reversesthe Severityof
MyocardialInjuryaftarlschemia-Reperfusioni
Cholesterol-FedRabbits
J. Igarashi, S. Hoshida, M. Nishida, N. Yamashita, K. Aoki, M. Hori,
T. Kuzuya, M. Tada. Osaka University Medical School, Suita, Japan
3,4-Dihydro-8-(2-hydroW-3-isopropylamino)-propoxy-3-nitroxy-2H-l-benzopyran
(nipradilol) was designed to cancel the action of beta-adrenergic blockers on
vasculature by adding nitroxy residue to beta-blocker structure. We studied
the effects of chronic treatment with nipradilol (10 mgfkg/day) on the size of
infarct resulting from corona~ occlusion (30 rein) - reperfusion (48 h) in rab-
bits fed with/without 1% cholesterol for 10weeks. Propranolol (50 mg/k@day)
was used as a control. Infarct size in cholesterol-fed rabbits (69.9 + 3.8Y0,
n = 10) was significantly larger than that in noncholesterol-fed rabbits (48.8
+ 5.8%, n =9, p < 0.05). The augmentation of infarct size in cholesterol-fed
rabbits was markedly reversed by nipradilol (49.2 + 6.4%, n = 9, p < 0.05),
but not by propranolol (54.9 + 6.3%, n =9, n.s.). In noncholesterol-fsd rab-
bits, neither nipradilol nor propranolol affected the infarct size (52.5 + 4.6%
and 61.9 + 7.2%, respectively, n.S.). There were no significant differences
in the area at risk and in hemodynamic data during the course of experi-
ment among all groups. Acetylcholine (10-5 M)-induced relaxation of aorta
was markedly impaired in cholesterol-fed rabbits (57 & 5 vs. 95 * 4%, p c
0.05), which was completely reversed by nipradilol (96 + 5%, p c 0.05). We
also studied whether or not nipradilol releases nitric oxide (NO) in smooth
muscle cells. When cultures of rat aortic smooth muscle cells were treated
with nipradilol (0.5 mM), nitrite concentration in the culture media significantly
increased from 0.0 + 0.3 to 36.0 + 0.9 nmol/mg prot (p < 0.05), resulting in
marked increase in cGMP content. These results demonstrate that chronic
treatment with nipradilol of atherosclerotic animals could reverae the severity
of myooardial injury after ischemia-reperfusion. These beneficial effects of
nipradilol upon myocardial injury might be associated with its potency ae a
NO releasing agent.
11027-1761 AntihypetlensiveandVaSCUlarEffeCtSOf
ETA-ReceptorBlockadein DahlSalt-Sensitive
Hypertension
L.V.d’Uscio, P.Moreau, M. Batton, T.F.Luscher. Cardiobg~ Cardiovascular
Research, University Hospital, Bern, Switzerland
The involvementof endothelin(ET) in hypertensionis still unclear.Our
objectivewas to determinethe effectof a new,orally available,selective
ETA-receptorantagonist,LU135252,on the bloodpressureelevationand
the changesof vascularstructurein a modelof salt-inducedhypertension.
Dahlsalt-sensitive(DS)and Dahlsalt-resistantrats(DR)weretreatedfor 8
weekswith4Y.NaClaloneor in combinationwithLU135252(60m@g/day
in the chow).Placebo-treatedratsservedas controls(n = 6-6/group).The
basilaranda smallmesentericartery(lumendiameterof 200and250-300
ym, respectively)were isolatedand their geomet~ studiedin vitro under
perfusedand pressurizedconditions.Chronicsaltadministrationincreased
systolicbloodpressureby37 + 3 mmHgin DSrats,as comparedto 1 + 2
mmHgin controlDS rats(p < 0.05;tail cuffmethod).This increasewas in
partpreventedby concomitantLU135252administration(19 + 3 mmHg;p
<0.05 vs salt-treatedDSrats).The meditilumenratioof the basilarartery
increasedin theDSratson4% NaCl diet by eutrophic remodeling; vascular
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hypertrophy was absent (growth index: 5 * 4%, n.s.). In the mesenteric
artery the increased meditilumen ratio was also observed, but involved
hypertrophic remodeling (growth index: 32 + 10%, p < 0.05). The ETA-
reeeptor antagonist LU135252 prevented the structural changes in both
vascular beds (p <0.05 vs salt-treated DS rats). The mediahmen ratio was
significantly correlated with systolic blood pressure in basilar (r = 0.53, p
<0.01, linear regression) and mesenteric arteries (r = 0.79, p < 0.0001).
LU135252 had noeffectin the normotensive DR rats. These findings suggest
that the long-term pressor effect of salt administration is mediated, in part, by
the action of endogenous ET,acting on ETA-receptors.Thus, selective ETA-
receptor antagonists may be therapeutically useful to lower arterial pressure
and improve vascular remodeling of resistance arteries in salt sensitive
individuals.
1027-177 Poor Regression in Hypertensive Alcoholic Rsts
on Lisinopril Therspy
V.B. Patel 1, G.S. Sandhu, J.M. Corbett2, M.J. Dunn2, P.J. Richardson3,
V.R. Preedy’. 1Department of Clinica/Biocfremistry King’s Co//age
Hospita/, London, UK, 3 Department of Cardiology King’s College Hospital,
London, UK, 2 Department of CafcfiothoracicSurgery Harefie/d Hospita/,
Middlesex, UK
Hypertensive subjeets who are also alcoholics are poorly managed. The
mechanisms for this are unknown, but we hypothesised an interaction at
the contractile-protein level. We tested this theory in the following groups;
(a) SHR control, (b) SHR + alcohol, (c) SHR control + Iisinopril, (d) SHR +
alcohol + Iisinopril. Alcohol was administered for 6 weeks and constituted
35% of total calories. Lisinopril was given”in the diet at a doae of 5 mg/kg
Imfy weight. After 6 weeks the myofibrillary frsctions were isolated by sub-
cellular fractionation. The myofibrillary fraction of the heart was analysed by
SDS-PAGE and produced 9 distinct contractile proteins. The results showed
reduced amounts of myosin heavy chain (–20%, P < 0.01), myosin light
chain (–24%, P c 0.01), and troponin (–21%, P < 0.01) in hypertensive
alcoholic rats in comparison to control hypertensive rats. Hypertensive rats
on Iiainopril therapy showed reductions in left ventricle weight (–36%, P <
0.001) and tisaue protein composition in comparison to control hypertensive
rats. However, animals on concomitant alcohol and Iiainopril had significantly
higher wet weights (+20%, P < 0.001) and myofibrillar protein content (+24~o,
P < 0.01) than hypetiensives on Iisinopril. Individual contractile proteins were
aLsohigher but failed to attain significance. In conclusion, hypertensive alco-
holic rats have impaired contractile composition. Alcoholic rata on Iisinopril
therapy show poor regression of contractile apparatus.
11027-1781 MyocmfialTisSueConcentrStionsOf
Amiodarone end Deeethylamiodarone After
Chronic Treatment: Correlation With Local
Action Potential Duration
M.R. Franz, S. Behrens, C. Li. VeteransAdministration and Georgetown
Urriversi~, Washington, DC, USA
To better understand the pharmacodynamic and electrophysiologic proper-
ties of amioderone (A), we determined the relationship between chronic A
treatment, myoeardial tissue concentration (TC) of A and its metabolizede-
sethylamiodarone (DEA), and the correlation between TC of A and DEA with
local myocsrdial depolarization effects. Six hearts of rabbits loaded with A
for 6 weeks (50 mg/kgfday) were isolated and Langendoti-perfused while
monophasic action potential durations (MAPDs) were measured simultane-
ously at 10 sites of both ventricles during regular pacing at 600 msec cycle
length. Each MAP recording site was marked and tissue excised for subse-
quent analysis of A and DEA TC using highdensity liquid chromatography.
A and DEA TC were widely disparate within a single heart and between
different hearts (range 1.2 to 35.6 wglg). Despite this variance, A and DEA
TC consistently were high,estwithin epicardial (11.2 * 7.6 @g), lowest in
midmyocsvdial (3.9 +2.3), and intermediate inendocardial tissue (4.6 + 3.5).
MAPD also varied widely within individual and all hearts, ranging from 133
to 210 msec despite constant 600 resee pacing. When the entire range of A
and DEA TC from all 6 hearts was correlated with MAPD, a highly significant
correlation was found between MAPD and DEA (r = 0.63, p < 0.0001) but
not between MAPD and A (r = 0.30, p = 0.04).
Conclusions: 1) Six-wwks of A treatment result in widely disparate TC of
both A and DEA within ventricular myooardium of a single hearts and within
different hearts. 2) DEA but not A is responsible for significant increase
in depolarization time. 3) MAPD distribution reflects thie dispersed TC and
accurately identifies the local depolarizationprolonging effect of DEA. 4) The
extremely heterogenoue myocardial tissue uptake of A and DEA may help
explain deficiencies in Atreatment effectiveness.
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m1028167 Effect of the Association of DifferentProgestogens to Estradiol 17glTherapy Upon
Effort-Induced Mvocardial Ischemia in Female
Patients with Co;onary Artery Disease
G.M.C. Rosano, S.L. Chierchia, GL. Morgagni, M. Gabriele, F. Leonardo,
P.M.Sarrel, P.Collins. Dept. of Cardiology kvituto Scientific H San
Raffae/e, fvfi/ano-f30rna,/ta/y Nationa/ Heart& Lung /nstitute, London, UK
Estrogens have a protective effect upon the cardiovascular system and
Estradiol 17B (E) has been shown to have vasoactive and anti-ischemic
properties, However, little is known on the cardiovascular effect of adding
progestogens to estrogens in order to reduce the likelihood of the latter to
facilitate uterine cancer, The aim of this randomized double-blind cross-over
study was to evaluate the effect of adjunctive therapy with Progesterone (P,
45 m~daily) ormedroxyprogesterone (MPA, 10 mgldaily) to E upon exercise-
induced myoeardial ischemia in 18 postmenopausal women with CAD. Two
pts were withdrawn during the MPA phase because of unstable angina.
Compared to baseline E alone increased time to 1 mm ST$ (325 + 156 vs
257 + 143 sac, p < 0.01). In 5 pts in whom the exercise test was negative
after E + P the test become positive during E + MPA (p < 0.01). Compared
to baseline E + P increased both time to 1 mm STJ.and exercise time (416
* 156 vs 257 + 143 see, p c 0.01 end 435 + 195 vs 365 + 198 see, p <
0.05, respectively). By contrast, no difference was found between baseline
and E + MPA in either time to 1 mm ST+ or exercise time (298 l 146 vs 257
+ 143 see, p = NS and 411 + 202 vs 365 + 198 see, p = NS, respectively).
In conclusion MPA but not natural P reverses the effect of chronic therapy
with E upon exercise-induced myocardial ischemia. The progestogen to use
in adjunct to E must be carefully chosen when menopausal pts with CAD are
prescribed hormone replacement therapy.
-[ Safety, Pfrarmacokinetics, andlmmunogenicity
of Intravenous Administration of h5G1.1-scFv in
Humana
J.C.K. Fitch, J,A. Elefteriades, L.A. Matis, M.J. Evans, H.M. Rinder,
S.A. Rollins, B.L. Alford, R.L. Hinea. Ya/eUniversity Schoo/ of Medicine and
Alexion Pharmaceuticals, Inc., New Haven, CT USA
Complement activation during cardiopulmonary bypaas (CPB) eontributea to
a systemic inflammato~ response associated with excessive bleeding, and
pulmonaty and cardiac dysfunction. This is the first human clinical report of
the safety, pharmacokinetice, and immunogenicity of a humanized single-
chain monoclinal antibody, designated h5Gl .l-ecFv, which blocks the gen-
eration of C5a and C5b-9. The antibody is being evaluated in two Phase I
studies. The initial study was designed as a single-blind, placebo-controlled,
ascending-dose study of h5Gl .I-scFv in healthy male volunteers. Subjects
received a single dose of h5G1.1-scFvor placebo administered intravenously
at one of four dose levels (0.2, 0.5, 1.0 or 2.0 mg/kg). In contrast to the very
rapid clearance normally observed following injection of single chain antibod-
ies, the h5Gl .I-scFv displayed a serum half life of greater than 10 hours,
presumably secondary to its vety high affinity binding to the larger C5 protein
in plasma. Prolonged systemic inhibition of the complement caacade was
achieved in a dose dependent manner. At the higheat dose, complement
dependent hemolyfic activity was completely inhibited for4 hours and signif-
icant inhibition was obsetved for greater than 12 hours. The follow-on atudy
was designed as a placebo-controlled, open-label, ascending dose study in
CABG patients. A total of 4 doses plus placetm were tested with 3 cohorts
in each dose. Safety date was assessed based on the WHO Recommenda-
tions. Assays were done to assess the extent of complement, leukocyte and
platelet activation aa well as fibrinolysis. Administration of h5G1.1-scFv up
to single intravenous dose of 2 mg/kg is safe and well tolerated. Based on
these preliminary biological effects, we propose that the use of an anti-C5
antibody will significantly reduce the impact of complement-mediated injuries
sustained during CPB. Further clinical studies will be carried out to delineate
the potential efficacy of an anti-C5 antibody.
